Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly Eloralintide in Adults with Moderate to Severe Obstructive Sleep Apnea and Obesity/Overweight
jRCT2011250063Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of eloralintide in obstructive sleep apnea hypopnea syndrome (OSAHS), obesity and Overweight (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percent Change from Baseline in Body Weight and Change from Baseline in Apnea-Hypopnea Index (AHI). Planned start May 2026; status: not yet recruiting.
02
Drugs
eloralintide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesityOverweight
Beyond the preview
Go deeper on jRCT2011250063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250063.